Health Condition 1: C169- Malignant neoplasm of stomach, unspecified
Conditions
Interventions
Intervention1: Quicobal: Arm 1 : Tablet Quicobal( Mecobalamin orally disintegrating strip)
Dose: 1500mcg Once daily
Duration: for 4 years or reaching study end point
Control Intervention1: Arm 2 Vit
Sponsors
Tata Memorial Hospital
Eligibility
Inclusion criteria
Inclusion criteria: Adult patients more than or equal to 18 years, males and females with baseline haemoglobin 13 plus minus 1.9 g/dl, 12±1.9 g/dl respectively undergone total gastrectomy/subtotal gastrectomy for gastric cancer. -Regular follow up as per study protocol. -Able to provide Written informed consent
Exclusion criteria
Exclusion criteria: -Patients with other kinds of oral supplementation (multi-vitamins) post surgery in less than 4 weeks before randomisation. -Males with Haemoglobin -Patients with known hypersensitivity to the formulation -Pregnant and lactating women -Patients with severe neurological manifestations due to vitamin B12 deficiency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary end point is to assess the drop in haemoglobin more than 2 g/dl in any armTimepoint: 4 years | — |
Secondary
| Measure | Time frame |
|---|---|
| QOL assessment (FACT G questionnaire) CBC (Change in Hb and MCV, ANC and platelet count) Changes in the Iron studies/parameters including iron, ferritin, TIBC, transferring saturation. Timepoint: 4 years | — |
Countries
India
Contacts
Public ContactVikas Ostwal
Tata Memorial Hospital
Outcome results
None listed